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Introduction
Results
The isolated species included C. albicans (n=198), C. glabrata (n=36), C. dubliniensis (n=11),
Candida tropicalis (n=4), Candida krusei (n=3) and either Candida kefyr, Candida parapsilopsis, or
Candida lusitaneae (n=2), with Cameroonian patients harbouring double the species of their South
African counterparts.
Drug resistance to different classes of antifungals was found to be widespread, especially in the case
of azole drugs.
Fluconazole-resistant Candida isolates run on SDS-PAGE expressed proteins with molecular weights
consistent with that of tropiase (a 24kDa acid proteinase enzyme associated with increased Candida
virulence) and exoglucanase (a 44kDa protein involved in host cell surface adhesion). In the case of
HPLC/MS, a much more detailed spectrum of fluconazole-resistance related proteins was identified,
ranging from multi-drug resistance efflux transporter CDR1 and CDR2 proteins and the elucidation
of Candida colonization mechanisms through the action of oxidoreductases that bind to mammalian
estrogen, heat shock proteins that bind to human salivary peptides and mediate their fungicidal
activity, pH-responsive proteins which may increase the pathogenic ability of the organisms and S-
(hydroxymethyl) glutathione dehydrogenase.
Conclusion
Methods
The study sample comprised of 254 African HIV-infected patients who presented at HIV
clinics with pseudomembranous plaque on the tongue or visible oral candidiasis. Ethics
approval for the study was obtained from the Research Committee at the University of
the Western Cape and the study complied with the Declaration of Helsinki (2013).
Confirmation of Candida species was achieved using conventional routine methods [2]
and C. albicans and C. dubliniensis isolates differentiated as previously described [3-5].
Drug susceptibility testing of the isolates was done using the TREK Sensititre®
YeastOne™ platform (Thermo Scientific, USA), a CLSI-approved broth micro-dilution
method that provides the minimal inhibitory concentration of nine antifungal drugs,
including azoles and echinocandins [6]. Proteomic analysis was performed using gel
electrophoresis (SDS-PAGE) and liquid chromatography – mass spectrometry
(HPLC/MS) [7] and proteins profiles compared between drug-susceptible and -resistant
isolates using the Uniprot protein database search.
Introduction: Candidiasis and HIV co-infection may cause increased patient morbidity
and mortality due to oropharyngeal or systemic dissemination. Limited information
exists on the prevalence, antifungal susceptibility profiles and drug resistance
mechanisms of Candida species on the African continent, the highest HIV-affected
region globally and home to new and emerging drug resistant Candida species.
Methods: Candida species isolated from the oral mucosa of HIV-positive African
patients were found to be resistant to many of the antifungals routinely used in HIV-
associated candidiasis. Candida cell membrane fractions were examined using sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and high performance
liquid chromatography mass spectrometry (HPLC/MS) in order to elucidate the cell
membrane proteins specifically expressed by antifungal drug resistant isolates.
Results: SDS-PAGE and HPLC/MS allowed for the identification of multi-drug
resistance efflux transporter CDR2 proteins and the elucidation of Candida colonization
mechanisms and pH-responsive proteins, with significant associations observed between
specific drug resistance and the duration of antiretroviral (ARV) therapy.
Conclusion: This study provided useful information on the mechanisms of antifungal
resistance in Candida species. It also formed the basis for further studies to address the
transfer of resistance between Candida species in an oral microbial biofilm.
According to the WHO [1], Sub-Saharan Africa has the highest rate of HIV infection
globally (71%), with Candida co-infection contributing to the increased morbidity and
mortality seen in immunocompromised individuals.
Access and availability of antimicrobial drugs is often limited in healthcare facilities in
most parts of Sub-Saharan Africa while in many parts of Africa, the sale of prescription
medications is largely unregulated thereby exacerbating the problem of indiscriminate
use and emerging resistance.
The expression of Candida proteins that are related to colonization and pathogenicity mechanisms
were found in most Candida species, with resistant species expressing further mechanisms of
resistance that allow for their survival when exposed to antifungals. This has serious implications for
HIV-associated candidiasis in patients on prolonged antiretroviral therapy.
Studies on the formation of Candida biofilms and the use of natural alternatives in combating
candidiasis and/or restoring the actions of antifungal drugs rendered ineffective due to drug
resistance are currently underway in our laboratories.
Fig.1. Sample collection (a), Candida species identification and differentiation by microscopy, germ tube test and growth on chromogenic and
differential media (b), VersaTREK MIC determination (c), proteomic analysis using SDS-PAGE and HPLC (d), Candida biofilm formation (e).
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